Sektor Lineage Cell Therapeutics, Inc.

Aktien

A2PP89

US53566P1093

LCTX

Biotechnologie

Markt geschlossen - 22:00:00 04.09.2026 % 5 Tage Veränd. 1. Jan.
1.080 USD -1.82% Intraday Chart für Lineage Cell Therapeutics, Inc. -2.70% -35.33%
Hauptkonkurrenten
% % 5 Tage Veränd. 1 Monat Veränd. 3 Monate % 1. Jan. % 1 Jahr Veränd. 3 Jahre Veränd. 5 Jahre Veränd. 10 Jahre Kap.($)
-1.82%-2.70%-3.57%-10.74%-35.33%-10.00%-19.40%-61.29%-62.11% 273 Mio.
-2.54%-2.84%+1.94%+15.43%+5.47%-1.90%+14.52%-26.22%+202.51% 48.93 Mrd.
-0.40%+1.03%+8.56%+34.90%+163.68%+439.20%+499.20%+621.72% - 45.01 Mrd.
-1.42%+2.30%+17.34%+43.28%+18.79%+45.46%+19.36%+1.73%+247.93% 44.07 Mrd.
-1.22%-2.31%+10.91%+27.98%+17.92%+12.40%+71.48%+6.52%+1’114.85% 40.73 Mrd.
+0.53%-1.36%+1.24%+6.57%+9.12%+16.04%+48.23%-19.16%+145.35% 33.52 Mrd.
-0.21%+9.14%+10.62%+23.63% - - - - - 17.77 Mrd.
-0.35%-1.56%+2.82%+28.91%+5.28%+22.59%+116.19%+202.96%+1’826.03% 16.5 Mrd.
-1.01%+0.50%+5.67%+11.81%+16.54%+15.83%+27.98%-40.73%+95.93% 14.67 Mrd.
-1.65%-1.03%+23.23%+55.28%+44.63%+77.75%+37.63%-35.82%+241.74% 13.77 Mrd.
+0.78%-3.04%+5.10%+7.89%-9.53%-6.53%-37.25%-37.17%+113.70% 12.72 Mrd.
-0.06%+0.91%+37.34%+23.65%+9.43%-17.28% - - - 11.66 Mrd.
-0.03%+0.11%+0.47%+36.20%+23.16%+36.87%-8.04%-43.53%+171.07% 11.36 Mrd.
-4.21%-5.92%+3.18%+79.24%+44.88%+38.92%+40.29%-49.77% - 10.39 Mrd.
-1.56%+0.21%-10.21%+16.26%-18.94%+34.07%+453.29%+206.92%+2’377.16% 10.61 Mrd.
-13.33%-10.17%+73.14%+142.19%+153.30%+85.06%+68.06%-12.00%+1’200.00% 8.77 Mrd.
-0.94%+2.05%+13.46%+32.88%+19.36%+663.31%+1’393.89%+9.39% - 9.82 Mrd.
+0.09%-0.64%+12.45%+57.34%+50.87%+178.18%+491.09%+95.52% - 9.76 Mrd.
-0.07%-4.85%+5.48%-22.68%-26.57%-2.12%+43.43%+46.99%+97.18% 9.65 Mrd.
-2.07%+0.96%+7.30%+41.76%+66.84%+144.50%+645.75%+198.12%+1’106.29% 9.43 Mrd.
Durchschnitt -1.54%-0.86%+11.32%+32.59%+29.42%+93.28%+216.98%+59.12%+634.12% 18.97 Mrd.
Gewichteter Durchschnitt nach Marktkapitalisierung -1.25%-0.42%+10.06%+30.33%+36.93%+98.54%+176.16%+93.13%+569.00%
  1. Börse
  2. Aktien
  3. A2PP89 Aktie
  4. Sektor Lineage Cell Therapeutics, Inc.